Multidrug-resistant bacteria play a significant role in public health by destroying the potency of existing antibiotics. Meanwhile, cancer remains one of the most common health problems that impact society, resulting in many deaths worldwide. Novel strategies are required to combat antimicrobial resistance and create efficient anticancer drugs that could revolutionize treatment. Nanomedicine is one such innovation that plays a significant role in developing alternative and more effective treatment strategies for antimicrobial resistance and cancer theranostics. The Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer is an essential scholarly resource that examines (1) how to overcome the existing, traditional approaches to combat antimicrobial resistance and cancer; (2) how to apply multiple mechanisms to target the cancer cells and microbes; and (3) how the nanomaterials can be used as carriers. Featuring a range of topics such as bacteriophage, nanomedicine, and oncology, this book is ideal for molecular biologists, microbiologists, nanotechnologists, academicians, chemists, pharmacists, oncologists, researchers, healthcare professionals, and students.

An illuminating guide for those newly diagnosed with prostate cancer as well as their partners and caregivers—one filled with extensive details about diagnosis, treatments, and tips for thriving. The second leading cause of cancer death for men, prostate cancer affects more than a quarter of a million individuals in the United States each year. Most men with prostate cancer will go through the journey from diagnosis through treatment and beyond with a partner and family members by their side. But there are few resources available that address the needs of both those with cancer and their loved ones who want to help. Written in accessible language and backed by the latest scientific research, Prostate Cancer covers • symptoms, diagnosis, and testing; • the full range of treatment options available; • practical tools partners can use to assist their loved one; • advice on managing the side effects of treatment, including incontinence and sexual problems; • tips to help cope with the emotional challenges associated with cancer; • recommendations for keeping healthy with diet, exercise, and mindfulness; and • insights into insurance issues. With three leading experts in urology, surgery, and psychiatry as its coauthors, Prostate Cancer provides the information and guidance you need to better understand the disease, communicate with health care providers, and support yourself and your loved one through treatment and survivorship.

Lanzkowsky's Manual of Pediatric Hematology and Oncology, Seventh Edition remains the go-to clinical manual for the treatment and management of childhood cancers and blood disorders. It is a comprehensive book on patient management, replete with algorithms and flow diagrams, and includes a new section on vascular anomalies. Reflecting the considerable advances in the treatment and management of hematologic and oncologic diseases in children, the seventh edition of this successful clinical manual is entirely updated to incorporate all current treatment protocols, new drugs, and management approaches. Its concise and easy-to-read format, again, enables readers to make accurate diagnoses and treatment decisions without having to reference larger medical textbooks.

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.

The Understanding, Prevention and Control of Human Cancer is an account of how a married couple opened understanding of environmental carcinogenesis. Elizabeth Cavert and James A. Miller showed that enzymes of the human body activate and enable otherwise benign organic chemicals to combine with DNA in such a manner that cancer results. Their work is of particular note because cancer causes more loss of life-years than the sum of all other causes of death-and, as the President's (USA) Cancer Panel warned, environmental carcinogenesis is a form of cancer that has been previously "grossly underestimated". The Millers' cancer research led to tests that identify dangerous chemicals which in turn permits prevention and thus the control of human cancer.

Advanced Drug Delivery Systems in the Management of Cancer discusses recent developments in nanomedicine and nano-based drug delivery systems used in the treatment of cancers affecting the blood, lungs, brain, and kidneys. The research presented in this book includes international collaborations in the area of novel drug delivery for the treatment of cancer. Cancer therapy remains one of the greatest challenges in modern medicine, as successful treatment requires the elimination of malignant cells that are closely related to normal cells within the body. Advanced drug delivery systems are carriers for a wide range of pharmacotherapies used in many applications, including cancer treatment. The use of such carrier systems in cancer treatment is growing rapidly as they help overcome the limitations associated with conventional drug delivery systems. Some of the conventional limitations that these advanced drug delivery systems help overcome include nonspecific targeting, systemic toxicity, poor oral bioavailability, reduced efficacy, and low therapeutic index. This book begins with a brief introduction to cancer biology. This is followed by an overview of the current landscape in pharmacotherapy for the cancer management. The need for advanced drug delivery systems in oncology and cancer treatment is established, and the systems that can be used for several specific cancers are discussed. Several chapters of the book are devoted to discussing the latest technologies and advances in nanotechnology. These include practical solutions on how to design a more effective nanocarrier for the drugs used in cancer therapeutics. Each chapter is written with the goal of informing readers about the latest advancements in drug delivery system technologies while reinforcing understanding through various detailed tables, figures, and illustrations. Advanced Drug Delivery Systems in the Management of Cancer is a valuable resource for anyone working in the fields of cancer biology and drug delivery, whether in academia, research, or industry. The book will be especially useful for researchers in drug formulation and drug delivery as well as for biological and translational researchers working in the field of cancer.

A behind-the-scenes look inside three key trials involving Monsanto's weed killer Roundup, cancer, and the search for justice—written by an expert witness medical oncologist who lived it all. For years, Monsanto declared that their product Roundup, the world's most widely used weed killer, was safe. But that all changed in 2015, when the International Agency for Research on Cancer (IARC) analyzed data from scientific studies and concluded that glyphosate, the active ingredient in Roundup, is probably carcinogenic. The Environmental Protection Agency (EPA) disagreed, other regulatory agencies got involved, and scientists clamored to understand the link between glyphosate and cancer. Toxic Exposure tells the true story of numerous patients who developed non-Hodgkin lymphoma, a form of cancer, after using Roundup and their ensuing trials against Monsanto (now owned by Bayer, one of the largest agrochemical companies in the world). Written by Chadi Nabhan, MD, MBA, a cancer specialist, this is the only book written by an expert physician witness who testified in the first three trials against Monsanto. Dr. Nabhan takes the reader behind the scenes of these pivotal trials, explaining key features of the cases, including how Monsanto downplayed the IARC's scientific conclusions, may have worked to change how the EPA classified glyphosate, and conducted extensive PR campaigns designed to minimize the public's perception of the negative health effects of its product. He also provides details about the other expert witnesses who reviewed the evidence, analyzed the science, and stood up to this agricultural behemoth in the courtroom. Dr. Nabhan tells the inside story of corporate influence, courtroom drama, legal discourse, monumental verdicts, and the ensuing media frenzy surrounding this massive uncovering of the truth and the years of scientific and legal work that led up to it.

Volume 37 will provide details on the major chemical constituents of medicinal plants and their mechanism of action as the anticancer compounds. This special issue, in addition to the previous volume (volume 36 of The Enzyme series was on Natural Products and Cancer Signaling Targets: Isoprenoids, Polyphenols and Flavonoids), will highlight the significant advance made in the field in elucidating mechanisms of anticancer effect of the major phytochemicals.

The complexity of cancer demands an integrated approach from both a cancer biology standpoint and a pharmaceutical basis to understand the different anticancer modalities. Current research has been focused on conventional and newer anticancer modalities, recent discoveries in cancer research, and also the advancements in cancer treatment. There is a current need for more research on the advances in cancer therapeutics that bridge the gap between basic research (pharmaceutical drug development processes, regulatory issues, and translational experimentation) and clinical application. Recent promising discoveries such as immunotherapies, promising therapies undergoing clinical trials, synthetic lethality, carbon beam radiation, and other exciting targeted therapies are being studied to improve and advance the studies of modern cancer treatment. The Handbook of Research on Advancements in Cancer Therapeutics serves as a comprehensive guide in modern cancer treatment by combining and merging the knowledge from both cancer biology and the pharmacology of anticancer modalities. The chapters come from multi-disciplinary backgrounds, including scientists and clinicians from both academia and various industries, to discuss nascent personalized therapies and big data-driven cancer treatment. While highlighting topic areas that include cancer prevention, cancer therapeutics, and cancer treatments through the lenses of technology, medicine/drugs, and alternate therapies, this book is ideally intended for oncologists, radiation oncologists, surgical oncologists, and cancer biologists, along with practitioners, stakeholders, researchers, academicians, and students who are interested in understanding the most fundamental aspects of cancer and the available therapeutic opportunities.